Cadrenal Therapeutics Inc... (CVKD)
Cadrenal Therapeutics Common Stock Statistics
Share Statistics
Cadrenal Therapeutics Common Stock has 1.94M shares outstanding. The number of shares has increased by -88.26% in one year.
| Shares Outstanding | 1.94M |
| Shares Change (YoY) | -88.26% |
| Shares Change (QoQ) | 5.45% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 47 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 32.09K, so 1.65% of the outstanding shares have been sold short.
| Short Interest | 32.09K |
| Short % of Shares Out | 1.65% |
| Short % of Float | 2.23% |
| Short Ratio (days to cover) | 1.44 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -7.3 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 2.38 |
| P/FCF Ratio | -2.4 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cadrenal Therapeutics Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.77, with a Debt / Equity ratio of 0.
| Current Ratio | 3.77 |
| Quick Ratio | 3.77 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 132.23% in the last 52 weeks. The beta is 1.46, so Cadrenal Therapeutics Common Stock's price volatility has been higher than the market average.
| Beta | 1.46 |
| 52-Week Price Change | 132.23% |
| 50-Day Moving Average | 17.52 |
| 200-Day Moving Average | 14.15 |
| Relative Strength Index (RSI) | 47.42 |
| Average Volume (20 Days) | 32,293 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.96M |
| Net Income | n/a |
| EBITDA | -10.96M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -8.73 |
Balance Sheet
The company has 10.02M in cash and 0 in debt, giving a net cash position of 10.02M.
| Cash & Cash Equivalents | 10.02M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -25.72M |
| Total Assets | 10.12M |
| Working Capital | 7.43M |
Cash Flow
In the last 12 months, operating cash flow was -7.36M and capital expenditures 0, giving a free cash flow of -7.36M.
| Operating Cash Flow | -7.36M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.36M |
| FCF Per Share | -6.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CVKD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CVKD is $32, which is 97.4% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32 |
| Price Target Difference | 97.4% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 20, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | Aug 20, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | 1.27 |
| Piotroski F-Score | 1 |